Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578708 · ClinicalTrials.gov registry record · Phase 1
Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER
A Phase 1 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00578708: Completed Phase 1 study, sponsored by Abbott Medical Devices.
NCT00578708 is a Phase 1 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578708, a Phase 1 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.
Interventions
- DEVICE AMPLATZER Membranous VSD Occluder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2003-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00578708 record still lists
NCT00578708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 1 intervention - of which AMPLATZER Membranous VSD Occluder is the first listed.
NCT00578708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00578708 about?
NCT00578708 is a clinical study titled "Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER". The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.
What is the current status of trial NCT00578708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2003-09. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00578708?
The interventions under investigation include: AMPLATZER Membranous VSD Occluder (DEVICE).
Who is sponsoring clinical trial NCT00578708?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00578708's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia